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The adoptive transfer of chimeric antigen receptor T-
cells (CAR-Ts) has emerged as an extremely promising 
immunotherapeutic approach for the treatment of B-cell 
malignancies, and the remarkable versatility of this 
technique makes it potentially applicable to a wide 
range human diseases. Traditional CAR molecules 
couple the single-chain variable fragment (scFv) of a 
monoclonal antibody to one or more intracellular 
signaling domains derived from the T-cell receptor 
(TCR) complex and costimulatory molecules. When 
stably expressed on the surface of T-cells, CARs 
combine the antigen-binding properties of a monoclonal 
antibody with the effector and self-renewal properties of 
T-lymphocytes. The native TCR recognizes intracel-
lular peptide antigens that are presented on the cell sur-
face by the major histocompatibility complex (MHC). 
Because of the highly polymorphic nature of the 
MHC gene, a TCR specific for a given peptide-MHC 
complex would be unlikely to recognize the same anti-
gen when presented by another patient’s MHC. In 
contrast, the scFv of a CAR targets antigens directly ex-
pressed on the surface of tumor cells (without process-
ing and MHC presentation), allowing the same receptor 
to be used for all patients. Furthermore, in addition to 
proteins, the scFv of a CAR can also recognize carbohy-
drates and glycans, thereby greatly expanding the array 
of targetable antigens. Finally, the MHC-independent 
recognition of targeted antigens by CAR-Ts overcomes 
one of the major mechanisms of tumor escape, that is, 
the downregulation of MHC on tumor cells.
Immune surveillance and targeted immune responses 
are important in both preventing and suppressing many 
cancers; however, tumors may ultimately escape im-
mune recognition and destruction via multiple mecha-
nisms.1-3 It has, therefore, been a long-standing goal 
to devise ways to engineer components of the immune 
system to overcome tumor-associated evasion and sup-
pression strategies. Adoptively acquired immunity was 
first described in 1954,4 and the development of alloge-
neic hematopoietic stem cell transplantation (HSCT) 
beginning in the late 1960s represented the first major 
breakthrough in cellular immunotherapy. The concept 
of CAR-Ts was described in the mid-1980s.5,6 Many 
technical challenges prevented early clinical 
application however,7 and it is only in the past 5-years 
that the efficacy of CAR-Ts has been demonstrated in 
multiple clinical trials. The past decade has also seen 
significant advances in other areas of cancer immuno-
therapy, including the emergence of immune check-
point inhibitors and bi-specific antibodies. Taken 
together, these therapies have firmly established the 
enormous potential benefits of redirecting the immunesystem to target cancer cells, and the unprecedented
success of CD19-directed CAR-Ts has clearly demon-
strated the efficacy of adoptive cellular immunother-
apies in accomplishing this goal.
DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTORS
First-generation CARs. The native TCR is a
membrane-bound heterodimer comprised of an a-
chain and a b-chain. Antigen recognition by the
endogenous TCR of CD41 and CD81 T-cells is
restricted to peptides bound to polymorphic MHC
molecules on the surface of cells. Recognition of an
MHC-bound peptide antigen by the TCR leads to
downstream activation of kinase pathways via a
complex of noncovalently associated transmembrane
(TM) signaling molecules, including a heterodimer of
CD3ε and CD3d, a heterodimer of CD3ε and CD3g,
and a homodimer of z-chains. TCR engagement alone
is not sufficient to fully activate T-cells, however, and
a requisite second activation signal is provided when a
costimulatory receptor on the T-cell binds to its
cognate ligand on an antigen-presenting cell. CD28 is
the most well-characterized costimulatory receptor
and binds to either CD80 or CD86 on the surface of
antigen-presenting cells.8 CD80, CD86, and other
costimulatory molecules are generally not expressed
by tumor cells, however, and chronic TCR activation
in the absence of costimulation (or in the presence of
signaling via coinhibitory receptors such as cytotoxic
T-lymphocyte–associated protein 4 and programmed
cell death protein 1) leads to T-cell anergy or death.9,10
The first CARs developed in the mid-1980s consisted
of the variable region of a monoclonal antibody coupled
to the constant region (a- and b-chains) of the TCR.5,6
The extracellular component (ectodomain) was later
modified to include only a recombinant scFv from the
antigen-binding variable domains of both the heavy
and light chains of a monoclonal antibody. The scFv
was coupled to a TM domain, followed by an immunor-
eceptor tyrosine–based activation motif (ITAM) from
the TCR-z endodomain. Eshhar et al. initially demon-
strated that this chimeric protein, which they referred
to as a ‘‘T-body,’’ could induce antigen-dependent,
non-MHC-restricted T-cell activation, leading to both
interleukin-2 (IL-2) secretion and target cell lysis.11
This basic structurewas used inmany subsequent studies
and is now referred to as the first-generation CAR.
Clinical trials of first-generation CAR-Ts, initially
targeting the human immunodeficiency virus12 and later
targeting antigens such as carbonic anhydrase IX,
CD171, folate receptor a, and GD213-17 expressed in
solid tumors, as well CD19 and CD20 expressed by
B-cell malignancies,18,19 did not induce substantial
clinical responses, but did serve to highlight several 
challenges to be considered in subsequent iterations of 
CAR designs. One of the most significant problems was 
the limited persistence of CAR-Ts after infusion. Other 
setbacks included unexpected on-target but off-tumor 
toxicities.15,20 These trials have also provided us with 
long-term follow-up data related to the safety of certain 
aspects of CAR-T generation. Most CAR-T trials 
published to date have utilized g-retroviral or len-tiviral 
vectors to express CARs in human T-cells. Based on 
earlier experience in which g-retroviral vector-based 
gene therapy in hematopoietic stem cells led to the 
development of T-cell leukemia,21,22 there has been 
concern that the use of such vectors could cause 
insertional mutagenesis in CAR-Ts as well. It is thus re-
assuring that long-term follow-up of patients treated 
with first-generation human immunodeficiency virus–
targeted CAR-Ts (which had much better long-term 
persistence than most other first-generation CARs) did 
not reveal any evidence of vector-induced immortaliza-
tion of cells or enrichment of T-cells with CAR trans-
gene integration near genes implicated in growth 
control.23
Second- and third-generation CARs. The next stage of 
CAR design involved attempts to improve the 
activation and proliferation of CAR-Ts in vivo by the 
incorporation of costimulatory domains. The poor in 
vivo persistence of first-generation CAR-Ts was felt to 
be partially explained by T-cell anergy and death in the 
absence of costimulation. To test this hypothesis, 
Finney et al. designed a CAR that incorporated the 
CD28 cytoplasmic endodomains in tandem with the 
TCR-z endodomain. In vitro studies revealed that, in 
response to antigen stimulation, CAR-Ts which 
included the CD28 endodomain produced 20-times 
more IL-2 than those with the TCR-z endodomain 
alone.24 Stronger evidence supporting the benefits of 
incorporating the CD28 costimulatory domains was 
provided by a study in humans directly comparing an 
anti-CD19-z (first generation) and an anti-CD19-CD28-
z (second generation) CAR. In that study, patients with 
non-Hodgkin lymphoma (NHL) were simultaneously 
infused with both CAR-T products, and it was 
demonstrated that CD19-CD28-z CAR-Ts exhibited 
significantly greater expansion and persistence.25
Given promising results with the incorporation of the 
CD28 endodomain, alternative (or additional) signaling 
domains have also been evaluated. 4-1BB is a member 
of the tumor necrosis factor receptor family and was 
initially selected due to data supporting its role in pre-
venting activation-induced death, inducing expansion 
of CD81 cells, enhancing CD81 T-cell responses duringviral infection and allograft rejection, and contributing to
effective antitumor responses in animal models of
cancer.26 Imai et al. demonstrated in vitro that anti-
CD19–4-1BB–z CAR-Ts exhibited significantly greater
cytotoxicity toward B-lineage acute lymphoblastic leu-
kemia (B-ALL) cells and significantly greater IL-2
release, as comparedwith anti-CD19-zCAR-Ts.26 Other
costimulatory domains (eg, OX-40) have also been eval-
uated. CAR constructs which add a single costimulatory
domain to the first-generation backbone are known as
second-generation CARs, whereas those including two
costimulatory domains are referred to as third-
generation CARs. In addition to combining CD28 and
4-1BB, third-generation CARs have also incorporated
other costimulatory domains such as OX-40.27,28 Most
clinical trials conducted to date have utilized second-
generation CARs with either a CD28 or 4-1BB costimu-
latory signaling domain. Although the optimal choice of
costimulatory domains has not been fully elucidated, a
recent study at the Baylor College of Medicine in 6 pa-
tients with diffuse large B-cell lymphoma (DLBCL)
evaluated the simultaneous administration of second-
generation CD19-specific CD28-containing CAR-Ts
and third-generation CD19-specific CD28-plus 4-1BB-
containing CAR-Ts and found 23-fold (range 1.1- to
109-fold) higher expansion and correspondingly longer
persistence for the third-generation CAR-Ts.29 As dis-
cussed below, there are many additional design factors
that affect the function of CAR-Ts, which in addition to
variable clinical trial designs, make it difficult to directly
compare existing studies.
Additional design factors affecting CAR function. The
potential effects of various structural modifications on
CAR function have been extensively reviewed else-
where, and a detailed discussion is beyond the scope
of this article.20,30 Briefly, considerations in designing
the ectodomain of a CAR include the scFv used, its
affinity for the target antigen, and the specific binding
site on this antigen. Although most CARs have been
generated by using a scFv, other designs have utilized
single antigen-binding region domains,31 non-
antibody receptors, and even ligands for another
receptor.32 The scFvs used are most commonly
derived from murine monoclonal antibodies, although
humanized scFvs have also been used with the goal of
reducing the immunogenicity of the ectodomain.
Additionally, the length of the hinge region between
the scFv and the TM domain can affect the degree of
T-cell activation upon antigen recognition. The TM
domain itself is usually derived from the TCR-z, CD4,
CD8, or CD28 molecules, and the choice of TM
domain can also have a significant effect on CAR-T
effector function and stability.20
PRODUCTION OF CAR T-CELLS
Most clinical trials of CAR-Ts published to date have 
utilized unselected patient-derived (autologous) periph-
eral blood mononuclear cells, which are activated using 
anti-CD3 (OKT3) and anti-CD28 monoclonal anti-
bodies (either in soluble form, immobilized, or coated 
to the surface of beads)30 and engineered to express 
the CAR transgene using viral vectors. CAR-Ts are 
then expanded in vitro with recombinant cytokines.30 
There is significant variability in these processes be-
tween institutions, however, and the optimization of 
various steps involved in CAR-T production remains 
an area of active investigation.
Source of T-cells: allogeneic versus autologous 
CARs. Most reported trials of CAR-T therapy for B-cell 
malignancies have utilized autologous lymphocytes 
that have been expanded ex vivo, transduced to express 
a CAR transgene, and then reinfused into the patient. In 
the setting of prior allogeneic HSCT, several trials have 
also evaluated the use of allogeneic, donor-derived 
CD19-specific CAR-Ts in patients who have 
experienced, or are at high risk for experiencing, 
relapse of their disease.33-36 Although there are 
significant differences between these studies, a recent 
trial evaluating allogeneic CD19-specific CAR-Ts for 
adults with relapsed B-ALL following allogeneic 
HSCT demonstrated a minimal residual disease 
(MRD)–negative complete remission (CR) in 4 of 5 
treated patients.34 In addition to this approach, there 
has also been substantial interest in generating 
allogeneic CAR-Ts which lack expression of their 
native TCR, thereby allowing their infusion into 
unrelated patients without the risk of inducing graft-
versus-host disease. As discussed below, the generation 
of so-called ‘‘universal CARs’’ has recently been 
demonstrated via the use of several novel gene-editing 
techniques, and the first clinical application of 
‘‘universal’’ CD19-specific CAR-Ts was recently 
reported in pediatric B-ALL.37,38
Gene transfer techniques. Most CAR-T trials to date 
have used either lentiviral or g-retroviral vectors to 
deliver the CAR transgene into the genome of 
activated T-cells. Each vector allows for efficient gene 
delivery and contains a promoter leading to 
constitutive CAR expression. Although g-retroviral 
vectors, when compared with lentiviral vectors, have 
been shown to be associated with an increased risk of 
insertional mutagenesis in hematopoietic stem cells,39 
experience to date does not suggest any clinically-
relevant differences between CAR-Ts produced via 
transduction by g-retroviral versus lentiviral vectors, 
and long-term follow-up of patients treated with 
g-retrovirally transduced CARs supports the safety ofthis technique.23 Nonviral gene transfer techniques
such as the Sleeping Beauty35,40 and PiggyBac41
transposon/transposase systems are also being
evaluated; however, the efficiency of DNA integration
associated with these methods is generally low. Other
studies have used electroporation of naked plasmid
DNA; however, the efficiency of this technique is even
lower.42 It is also possible to transiently express a
CAR via electroporation of mRNA, which may prove
to be a valuable tool to more safely investigate
CAR-Ts specific for novel target antigens. Each of the
above gene transfer techniques involves random
insertion of the CAR transgene into the genome, and
variegated transgene expression via transcriptional
silencing and vector copy number variation43 has the
potential to contribute to constitutive signaling and
T-cell exhaustion, which could decrease CAR-T
persistence in vivo.44
Limitations of the above approaches have driven sub-
stantial interest in applying gene-editing tools such as
prokaryotic type II CRISPR (clustered regularly inter-
spaced short palindromic repeats) Cas9 (CRISPR-asso-
ciated protein 9) to the generation of CAR-Ts.45 Two
separate groups have recently demonstrated the use of
gene-editing tools to insert a CD19-specific CAR trans-
gene directly into the native TCR a-chain locus, thereby
simultaneously ‘‘knocking in’’ a CAR transgene and
knocking out the endogenous TCR.44,46 Eyquem
et al.44 accomplished this using CRISPR/Cas9 gene-
editing techniques, and MacLeod et al.46 used an engi-
neered homing endonuclease and an adeno-associated
virus template to target a CD19-specific CAR into the
TCR a-chain locus. A potential benefit of this approach
is the ability to place the CAR transgene under the con-
trol of endogenous regulatory elements, thereby poten-
tially reducing tonic signaling and associated T-cell
differentiation and exhaustion.44 To this end, Eyquem
et al. demonstrated that gene-edited cells had lower
but more uniform levels of CAR expression, and that
these cells significantly outperformed conventional ret-
rovirally transduced CARs in a mouse model of B-ALL.
It remains to be seen whether such approaches will offer
substantial clinical advantages as compared with non-
targeted CAR insertion in T-lymphocytes.
Ex vivo expansion and CAR T-cell subsets. Following
transduction, CAR-Ts are typically provided
intermittent cytokine stimulation with the goals of both
driving T-cell expansion and influencing the final
composition of T-cell subsets. The differentiation status
of adoptively transferred T-cells can have a profound
impact on their clinical activity and persistence in vivo.
Because unsorted peripheral blood mononuclear cells
are usually transduced, both CD41 and CD81 CAR-Ts
1 are simultaneously generated. Although CD8 effector
T-cells generally exhibit greater antitumor cytotoxicity 
in vitro, CD41 cells may play a role in vivo in 
promoting the persistence of CD81 T-cells. In addition, 
various studies have demonstrated that the adoptive 
transfer of less-differentiated T-cells leads to greater 
persistence and antitumor efficacy in vivo.47-50 The 
production of CAR-Ts for clinical use has traditionally 
involved T-cell expansion via stimulation with 
recombinant IL-2.30 The cytokines IL-7 and IL-15 have 
subsequently been demonstrated, by our group and 
others, to increase the frequency of 
CD81CD45RA1CCR71 T-cells, a phenotype 
corresponding to memory stem T-cells that, when 
compared with more differentiated T-cell subsets, was 
shown to correlate with enhanced in vivo persistence 
and antitumor activity.51,52 Because ex vivo expansion 
techniques remain an active area of investigation, there 
is significant heterogeneity in such techniques between 
studies, and consequently, in the composition of T-cell 
subsets found in the CAR-T products administered to 
patients thus far.
In an approach that differs from most other trials to 
date, investigators at the Fred Hutchinson Cancer 
Research Center (FHCRC)/Seattle Children’s are evalu-
ating the utility of selecting for and purifying different 
T-cell subsets before transduction rather than using cyto-
kine stimulation to drive the differentiation of unsorted
T-cells.53-55 In two ongoing trials, the investigators 
selected CD41 T-cells by positive immunomagnetic 
selection, selected CD81 central memory T-cell cells by 
depleting CD41, CD141, and CD45RA1 cells, and then 
selected for CD62L1 cells from the remaining fraction. 
They transduced the purified CD41 T-cells and CD81 
central memory T-cell cells separately, expanded them 
in vitro, and mixed them at a specific ratio before 
infusing the T-cell product into patients. Although this 
approach seems feasible, it remains to be seen whether 
such techniques would be broadly applicable and if they 
would offer significant advantages in terms of safety 
and efficacy compared with the use of unselected T-
cells.55ADMINISTRATION OF CAR T-CELLS
CAR-Ts are generally administered following lym-
phodepletion, which has been shown to improve both 
CAR-T persistence and antitumor activity.55,56 The 
administration of either total body irradiation or 
preparative chemotherapy regimens was initially 
demonstrated to improve antitumor responses in 
melanoma patients treated with autologous tumor-
infiltrating lymphocytes and IL-2, and this was shown 
to correlate with increasing circulating levels ofhomeostatic cytokines such as IL-7 and IL-15.56
Lymphodepletion is thought to directly affect the
survival, persistence, and proliferation of adoptively
transferred T-lymphocytes primarily via elimination of
cellular elements that compete for endogenous homeo-
static cytokines and by minimizing immune-mediated
CAR-T rejection.55,56 The limited antitumor efficacy
and CAR-T persistence seen in some early trials may
be at least partially explained by the lack of adequate
lymphodepletion.33,57 Most patients on recent trials
have been treated with lymphodepleting chemotherapy.
Although the combination of chemotherapy agents has
often been left to the investigator’s choice, the most
common regimens have included cyclophosphamide
with or without fludarabine.
The importance of adequate lymphodepletion is
further emphasized by a trial conducted at FHCRC in
which second-generation CD19-specific CAR-Ts were
administered to adult subjects with B-ALL. The initial
13 patients received lymphodepletion with cyclophos-
phamide alone. Although 83% of these patients
achieved a CR, 70% of them relapsed at a median of
66 days after CAR-T infusion, and this was associated
with the emergence of transgene-specific cytotoxic
CD81 T-cell–mediated immune responses.55,58 The
addition of fludarabine to the lymphodepletion
regimen for the subsequent 17 patients enrolled into
the study produced durable responses, with 71% of
these patients remaining in CR at a median follow-up
of 300 days.55 In a study conducted at the National Can-
cer Institute (NCI) of CD19-specific CAR-Ts for pedi-
atric patients with relapsed/refractory B-ALL, Lee
et al. also reported superior outcomes among patients
who received lymphodepletion with fludarabine plus
cyclophosphamide, compared with those receiving
alternative lymphodepletion regimens (median overall
survival 13.3 months versus 5.5 months, respectively).59TOXICITIES OF CAR T-CELLS
Despite significant clinical responses across multiple
clinical trials, the widespread use of CAR-T therapy has
thus far been prevented by both observed and theoretical
toxicities, including cytokine release syndrome (CRS),
neurotoxicity, and on-target off-tumor effects.60
Cytokine release syndromeandneurotoxicity. Cytokine
release syndrome is themost common and often themost
severe toxicity of CAR-T therapy in patients with
lymphoid malignancies, and is characterized by
increased levels of multiple pro-inflammatory
cytokines, including IL-6, interferon-gamma, tumor
necrosis factor, IL-2, IL-2-receptor-a, IL-8, and
IL-10.60 CRS can affect multiple organs, and can occur
anywhere from hours to more than 7 days following
CAR-T infusion. Mild cases of CRS produce flu-like 
symptoms; however, more severe cases may lead to 
hypotension, vascular leak, respiratory failure due to 
pulmonary edema and/or pneumonitis, renal 
insufficiency, and neurologic complications including 
delirium, hallucinations, ataxia, aphasia, and 
seizures.60 Multiple CRS grading systems have been 
proposed,61-63 complicating the direct comparison of 
CRS cases between trials. Of note, the Common 
Terminology Criteria for Adverse Events, Version 4.064 
criteria for grading CRS is applicable only to infusion 
reactions caused by monoclonal antibodies, and does 
not apply to adoptive cellular immunotherapy.60 
Brudno and Kochenderfer have recently published 
guidelines for managing patients with CRS and other 
toxicities associated with CAR-Ts.60 Tocilizumab, a 
monoclonal antibody targeting the interleukin-6 
receptor (IL-6R), is recommended for the initial 
treatment of CRS, with corticosteroids used for cases 
refractory to tocilizumab, and dexamethasone is 
specifically recommended for grade $3 neurologic 
toxicities.60 Corticosteroids may impair CAR-T 
expansion and persistence, and are thus avoided in 
milder cases of CRS.63,65 Although not yet evaluated in 
clinical trials, recent preclinical studies have suggested 
a potential benefit of the Bruton’s tyrosine kinase 
inhibitor, ibrutinib, and the JAK/STAT pathway 
inhibitor, ruxolitinib, in reducing CAR-T–mediated 
cytokine release and preventing CRS.66,67 Despite the 
use of tocilizumab and corticosteroids, severe CRS has 
led to several deaths in clinical trials of CD19-specific 
CAR-Ts, and 5 deaths due to unexpected severe 
neurologic toxicity recently prompted the 
discontinuation of a large phase II clinical trial in adult 
subjects with relapsed/refractory B-ALL.55,68-70 
Although neurotoxicity is frequently seen in the 
context of CRS, neurologic complications due to 
CD19-specific CAR-Ts have also occurred 
independently of other CRS symptoms. In a recent 
analysis of CRS in 39 pediatric subjects treated for 
B-ALL at the Children’s Hospital of Philadelphia 
(CHOP), grade $3 CRS was reported in 46% and 
encephalopathy was reported in 33% of patients, with 
encephalopathy most often occurring later in the course 
of CRS and after fevers had resolved.71 The 
pathogenesis of the serious neurologic complications 
seen with certain CAR-T products remains unclear.60,65 
Severe encephalopathy is unfortunately unresponsive 
to steroids in most cases and thus predictive models72 
and alternative treatment strategies are needed.
On-target toxicities. The widespread applicability of 
CAR-T therapy and its extension beyond B-cell 
malignancies has in large part been limited by thepaucity of known antigens that are truly specific to
tumor cells. Expression of target antigens on normal
tissues can lead to severe toxicity in the setting of
CAR-T therapy, as evidenced by early experience in
trials among patients with solid tumors.15,73 The
comparative success of CD19-specific CAR-Ts is
largely explained by the tolerability of associated on-
target toxicities. CD19 is an extracellular glycoprotein
whose expression is limited to normal B-cells and
malignant B-cell clones, and aplasia of normal B-cells
resulting from successful treatment with CD19-
specific CAR-Ts can be effectively managed with the
use of intravenous immunoglobulin infusions.
Similarly, in a trial of CAR-Ts targeting the k-light
chain of human immunoglobulins, on-target toxicities
led to the elimination of normal k-expressing (but not
l-expressing) B-cells.74 Given the rapidly expanding
field of CAR-T therapies, and ongoing clinical trials
evaluating novel antigenic targets for both
hematologic malignancies and solid tumors,75 on-
target toxicities will continue to be a major concern.
As discussed below, there has consequently been
significant interest in the incorporation of various
safety mechanisms into CAR designs with the goal of
mitigating any observed toxicities.
Safety strategies. Given the potential for life-
threatening, and often unpredictable toxicities
associated with CAR-T therapy, a compelling strategy
to improve the safety of such therapy has been the
addition of ‘‘elimination’’ or ‘‘suicide’’ genes into
CAR constructs.
The herpes simplex virus thymidine kinase (HSV-tk)
was the first such transgene to be evaluated in the
context of cellular therapy.76 HSV-tk-expressing lym-
phocytes can be killed by administration of the pro-
drug, ganciclovir, leading to accumulation of toxic
metabolites and disruption of DNA synthesis in
dividing cells. While this approach has been evaluated
clinically in the context of HSCT,77 disadvantages
include the slow onset of action (due to effects only
on diving cells), transgene immunogenicity limiting
the in vivo persistence of HSV-tk–expressing cells,78
and the potential interference with alternative clinical
use of ganciclovir.
One more promising approach has been the inclusion
of an inducible caspase-9 (iC9) safety switch, which is
based on a modified human caspase-9 gene fused to
the human FK506 binding protein. When incorporated
into a CAR, dimerization of iC9, and subsequent
apoptosis of the expressing cells, can be induced by a
chemical inducer of dimerization known as AP1903/Ri-
miducid (Bellicum Pharmaceuticals). In a humanized
mouse model, our group recently demonstrated the
ability of AP1903 to eliminate iC9-containing CD19-
specific CAR-Ts in a dose-dependent manner, thus al-
lowing the selective containment of CAR-T expansion 
when clinically appropriate (eg, mild CRS) or the com-
plete deletion of the CAR-Ts to allow B-cell reconstitu-
tion.79 The iC9 system has been evaluated clinically in 
the setting of allogeneic HSCT.80 There are currently 
several registered clinical trials evaluating the iC9 gene 
in the context of CAR-T therapy for solid tu-mors81-83 
and hematologic malignancies,84-86 including a trial of 
an iC9-containing CD19-directed CAR for the 
treatment of relapsed/refractory acute lymphoblastic 
leukemia that our group will be opening at the 
University of North Carolina.86
Another strategy to improve the safety of CAR-Ts has 
been the incorporation of a truncated form of the 
epidermal growth factor receptor (EGFRt), with the 
goal of allowing CAR-Ts to be eliminated in case of 
toxicity via administration of the anti-EGFR mono-
clonal antibody, cetuximab.87 The EGFRt domain was 
included in a recent CD19-directed CAR-T product 
evaluated in clinical trials at the FHCRC/Seattle Chil-
dren’s Hospital;53,55 however, the administration of 
cetuximab was not reported despite the occurrence of 
2 treatment-related deaths due to severe CRS and irre-
versible neurologic toxicity, respectively.55
CLINICAL TRIALS OF CAR T-CELLS FOR B-CELL 
MALIGNANCIES
Early clinical trial experience. Although initial clinical 
trials of CAR-Ts focused on patients with solid 
tumors,17 the most impressive clinical results to date 
have occurred in the treatment of B-cell malignancies. 
As noted above, this is in large part due the ideal 
candidacy of CD19 as a target for CAR-Ts. The initial 
experience with CAR-Ts in B-cell malignancies came 
from a trial conducted in 2008 by investigators at the 
City of Hope and FHCRC in which a first-generation 
CD20-specific CAR was evaluated in 7 patients with 
relapsed or refractory follicular lymphoma (FL).18 
Although efficacy was limited (1 patient achieved a 
partial response [PR] and no patient developed any 
significant B-cell aplasia), there were also no grade$3 
adverse events reported and CAR-Ts persisted up to 5–
9 weeks in 4 of 7 patients. The potential toxicity of 
CAR-Ts was highlighted early, however, by a report 
from the Memorial Sloan Kettering Cancer Center 
(MSKCC) describing the death, due to symptoms 
consistent with CRS, of a patient with chronic 
lymphocytic leukemia (CLL) who was treated with 
cyclophosphamide followed by infusion of CD19-
CD28-z second-generation CAR-Ts.88 In 2010, Jensen 
et al. reported their experience in treating 2 patientswith DLBCL with first-generation CD20-specific
CAR-Ts and 2 patients with refractory FL with
CD19-specific CAR-Ts. As with most trials of first-
generation CAR-Ts, in vivo persistence was poor
(1–7 days). Although this may be at least partially
explained by antitransgene immune responses
observed in 2 patients, it is unknown whether this
activity was directed at the CAR or an included
hygromycin resistance gene.19 In 2010, Kochenderfer
et al. at the NCI published an early report of success in
which a patient with FL was treated with a CD19-
specific CD28-z-containing second-generation CAR-T
product following lymphodepleting chemotherapy
with cyclophosphamide and fludarabine. The authors
demonstrated CAR-T persistence until 27 weeks
following initial infusion, which was associated with a
PR of the patient’s lymphoma and, most notably, the
development of isolated B-cell aplasia (used as a
surrogate marker for CD19 CAR-T persistence and
cytotoxic activity) lasting until 39 weeks.36 It was not
until 2011, however, that the enormous potential of
CAR-T therapy was initially demonstrated by the
preliminary results of a landmark trial from the
University of Pennsylvania (UPenn).89,90 In this trial,
patients with advanced chemotherapy-resistant CLL
were treated, following lymphodepleting
chemotherapy, with T-cells lentivirally transduced with
a second-generation 4-1BB-z-containing CAR.89,90
The authors demonstrated significant (.1000 fold)
in vivo CAR-T expansion, B-cell aplasia, and tumor
lysis syndrome, and reported that 2 of the initial 3
patients achieved a CR lasting .10 months. Mature
trial results published in 2015 showed an overall
response rate (ORR) of 57%, with 4 of 14 patients
achieving a CR that was negative for MRD, and a
median progression-free survival of 7 months.62
Although the earliest successes were reported in NHL
and CLL, the most impressive results with CAR-T
therapy to date have been seen with second-generation
CD19-specific CAR-Ts for relapsed and refractory
B-ALL for both children and adults, initially
demonstrated in trials at CHOP91,92 and the University
of Pennsylvania.63,92 Significant efficacy has also been
demonstrated in DLBCL and indolent B-cell
lymphomas.93
Clinical trials of CD19-specific CAR T-cells. Clinical tri-
als of CD19-specific CAR-Ts are summarized in detail
in Tables I and II. Outcomes have been reported for
over 350 patients with B-ALL and over 200 patients
with NHL/CLL. There is significant heterogeneity
between these trials, including differences in the CAR
design, T-cell subsets, lymphodepletion regimens,
autologous vs allogeneic T-cells, and the dose of
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Abbreviations: ALL, acute lymphoblastic lymphoma; allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplant; BCM, Baylor
College of Medicine; CAR-T, chimeric antigen receptor T-cell; CE, cyclophosphamide 1 etoposide; costim., costimulatory; CPLAGH, Chinese PLA General Hospital; CHOP, Children’s Hospital
of Philadelphia; CR, complete response or complete remission; CRi, complete remission with incomplete count recovery; Cy, cyclophosphamide; dz, disease; etop, etoposoide; FLAG,
fludarabine 1 cytarabine 1 granulocyte colony-stimulating factor; Flu, fludarabine; FluCy, fludarabine 1 cyclophosphamide; f/u, follow-up; GIMI, Shenzhen Genoimmune Medical Institute
(Shenzhen, China); Gr, grade; HYLDH, Hebei Yanda Lu Daopei Hospital; IC, investigator’s choice; ifos, ifosfamide; LV, lentivirus; MDACC, MD Anderson Cancer Center; mo, months; MSKCC,
Memorial Sloan Kettering Cancer Center; MRD, minimal residual disease; MRD(2), negative evaluation for minimal residual disease; NCI, National Cancer Institute; NE, not evaluable; NR, not
reported;ORR, overall response rate (PR or better);OS, overall survival; PR, partial response; pt, patient; r/r, relapsed and/or refractory; RFS, relapse-free survival; RV, retrovirus; SB, Sleeping Beauty;
scFv, single-chain variable fragment; sCRS, severe CRS (requiring ICU management, treatment with tocilizumab and/or corticosteroids); TALEN, transcription activator-like effector nuclease; UP-
enn, University of Pennsylvania.
Allogeneic CAR-Ts are derived from patient’s donor for prior allo-HSCT (except University College London study). Year refers to year most recent results were reported.











2012 NCI110 CD19 Adults: B-NHL or
CLL, n 5 8
(4 CLL, 3 FL, 1
SMZL)
FMC63/CD28 RV FluCy (Flu
25 mg/m2 3




















FL, n 5 2; sMZL,
n 5 1)




HSCT, n 5 4
FMC63/CD28 RV None 6.8 3 107–
1.13 3 108/kg
(allogeneic)
No Gr $ 3
toxicities
reported




2013 NCI36 CD19 Adults: persistent
B-NHL or CLL
after allo-HSCT,
n 5 15 (4 CLL, 2
DLBCL, 4 MCL)







2/15; Gr $ 3
hypoxia: 1/15
ORR: 2/10; CR: 1/10
(CLL, duration
91 mo); PR: 1
(MCL, duration
31 mo)
2015 MSKCC111 CD19 Adults: poor-risk
aggressive r/r






(n 5 7) vs 1 3





ORR: 5/8; CR: 5/8
(duration 101 to
181 mo)
2015 NCI93 (Kite) CD19 Adults: B-NHL or





FMC63/CD28 RV FluCy (Flu
25 mg/m2 3
5, Cy 60 vs






4/15, Gr $ 3
hypoxia: 2/15,
Gr $ 3 neurologic
toxicity: 6/15;
Tocilizumab: 2/15
ORR: 11/13 (2 NE);
CR: 4/7 DLBCL
(duration 6 to





2015 UPenn62 CD19 Adults: r/r CLL,
n 5 14
FMC63/4-1BB LV IC (Bend, n 5 6;
FluCy, n 5 3;






Gr 3 CRS: 2/14;









ORR: 8/14; CR: 4/




29 mo; 18 mo OS:
71%














Gr 2 CRS: 2/6; No
neurotoxicity
reported
ORR: 4/5; CR: 2/5 (1
NE), longest
91 mo; continued
CR: 1/5; PR 1/5;
3rd gen CAR-Ts
had mean 23-













































Gr $ 3 toxicities
observed other
than hypokalemia
(n 5 1), herpes
zoster (n 5 1)
ORR: 9/11;
CR: 6/11 (duration




























(n 5 15), Flu
(n 5 2), Cy
(n 5 1)























n 5 32 (21
DLBCL,
5 FL, 4 MCL)
FMC63/4-1BB
(EGFRt)
LV Cy, CE, or
FluCy






















2/5 FL, 0/4 MCL);














(n 5 2) HSCT
for B-NHL (4
DLBCL,
3 FL, 1 MCL),
1 nHL
FMC63/CD28 SB Following HSCT
(preparative
regimen IC)










26 mo at last
follow-up), 0/2
allogeneic
2016 MSKCC117 CD19 Adults: r/r
CLL, n 5 11
SJ25C1/CD28 RV FluCy (n 5 3),
Cy (n 5 6),
Bend (n 5 2); 1



























2 3 106 g
(targe
Any Gr CRS:










CD19 Adults: r/r B-NHL,
n 5 14 (13
DLBCL, 1 MCL)
FMC63/4-1BB LV FluCy (Flu
30 mg/m2, Cy
300 mg/m2)
5 3 107 g Gr 1–2 CRS:
3 (grading system
NR) Gr$ 3 CRS: 0
Gr $ 3
neurotoxicity:
2 (1 Gr 4
encephalopathy, 1
Gr 4 seizure)
DLBCL (n 5 13,






MCL – ORR: 0/1








4 3 105 .2 3
106/k
CRS not graded;
Gr$ 3 fever: 4/15;
Gr $ 3
tachycardia:
3/15; Gr $ 3
hypotension
3/15; Gr $ 3
headache 1/15
ORR: 4/15;





2016 NCI120 (Kite) CD19 Adults:
B-NHL, n 5 22
(19 DLBCL, 2
FL, 1 MCL)
FMC63/CD28 RV FluCy (Flu 30
mg/m2 3 3, Cy
300 vs 500
mg/m2 3 3)















2/2 FL, 1/1 MCL);
PR: 4/19 DLBCL
2016 NCI121 CD19 Adults: B-NHL,
n 5 9





LV FluCy (Flu 30
mg/m2 3 3, Cy
300 mg/m2 3 3)
6.6 3 1 –
2.0 3 06/kg
Any Gr CRS (NCI61):
9/8 (1 NE); Gr 3–4
CRS: 3/8
ORR: 6/8 (1 NE); CR:
2/7 (duration
21 mo)
2016 Upenn122,123 CD19 Adults: r/r
CLL, n 5 35
FMC63/4-1BB LV IC 5 3 107 s
5 3 1 8
(phas I);













































2016 Upenn124-127 CD19 Adults: r/r NHL,
n 5 27 (13
DLBCL,125 14
FL126)









9/13; Gr $ 3
CRS: 1/13; Gr$ 3
Neurotoxicity: 1/
13. FL – Any
Gr CRS: 6/14










FL – ORR: 11/14;





DLBCL, n 5 7
FMC63/CD28 RV FluCy (Flu 30
mg/m2, Cy
500 mg/m2)
1.1 3 106–2.0 3
106/kg (target:
2.0 3 106)
Any Gr CRS (NCI61):
6/7; Gr $ 3
CRS: 1/7; Gr $ 3
neurotoxicity: 4/7;













Abbreviations: allo-HSCT, allogeneic hematopoietic stemcell transplantation; auto-HSCT, autologous hematopoietic stemcell transplant; B-NHL, B-cell non-Hodgkin lymphoma; BCM, Baylor Col-
lege of Medicine; BEAM, carmustine, etoposide, cytarabine, and melphalan; Bend, bendamustine; CAR-T, chimeric antigen receptor T-cell; CE, cyclophosphamide 1 etoposide; chemo,
chemotherapy; costim., costimulatory; CPLAGH, Chinese PLA General Hospital; CHOP, Children’s Hospital of Philadelphia; CLL, chronic lymphocytic leukemia; CR, complete response or com-
plete remission;Cy, cyclophosphamide; DLBCL, diffuse large B-cell lymphoma; dz, disease; FL, follicular lymphoma; Flu, fludarabine; FluCy, fludarabine1 cyclophosphamide; f/u, follow-up; gen,
generation; Gr, grade; HDT-ASCT, high-dose therapy and autologous stem cell transplant; HSCT, hematopoietic stem cell transplantation; IC, investigator’s choice; ifos, ifosfamide; LV, lentivirus;
MCL, mantle cell lymphoma;MDACC, MDAnderson Cancer Center;mo, months;MSKCC, Memorial Sloan KetteringCancer Center;MRD, minimal residual disease;MRD(2), negative evaluation
for minimal residual disease; NCI, National Cancer Institute; NE, not evaluable; NR, not reported; nHL, nodular Hodgkin Lymphoma; NHL, non-Hodgkin lymphoma; NR, not reported; ORR, overall
response rate (PR or better);OS, overall survival; pen, pentostatin; PMBCL, Primary Mediastinal B-Cell Lymphoma; PR, partial response; pt, patient; r/r, relapsed and/or refractory; RFS, relapse-free
survival; RV, retrovirus; SB, Sleeping Beauty; scFv, single-chain variable fragment; sCRS, severe CRS (requiring ICU management, treatment with tocilizumab and/or corticosteroids); sMZL, splenic
marginal zone lymphoma; UPenn, University of Pennsylvania.
Allogeneic CAR-Ts are derived from patient’s donor for prior allo-HSCT. Year refers to year most recent results were reported.
CAR-Ts administered. Rates of CR in larger trials have 
ranged from 50% to over 90%. Considering all pediatric 
and adult patients in aggregate who were treated with 
CD19-specific CAR-Ts in the United States, we 
estimate the combined rate of CR or continued CR to be 
close to 80%, with a rate of MRD-negative CR of over 
60%. Efficacy for B-NHL and CLL is somewhat lower, 
with an estimated ORR around 60% across reported 
trials.
Toxicity rates have varied significantly across studies, 
likely reflecting the differences in the various factors 
described above. The median rate of severe or grade$3 
CRS is around 25% based on available data, and has 
ranged from less than 15%59 to over 70%68 (although 
differences may be partly explained by varia-tion in 
grading systems). At least 10 treatment-related deaths 
have occurred, predominantly among subjects with B-
ALL.
To date, MSKCC, FHCRC, and UPenn have reported 
on the largest number of adult B-ALL patients treated 
with CD19-specific CAR-Ts. At the 2016 annual 
meeting of the American Society of Clinical Oncology 
(ASCO), investigators from MSKCC presented an up-
date of their experience treating 51 adult patients with 
relapsed or refractory CD191 B-ALL with second-
generation CD19-specific CAR-Ts containing the CD28 
costimulatory domain.103 Sixty-one percent of patients 
had morphologic disease at the time of T-cell infusion, 
with the remainder having evidence of MRD. The 
median age for patients in the morphologic disease 
cohort was 40 and the median age in the mini-mal 
disease cohort was 53. Median follow-up was 8.5 
months (range 1–54 months) and 17 of 50 evaluable 
patients had $1 year of follow up. Patients with 
morphologic disease had received a median of 3 previ-
ous lines of therapy, whereas those in the minimal dis-
ease cohort had received a median of 2 previous lines of 
therapy. This included prior blinatumomab in 12 of 51 
patients and prior allogeneic HSCT in 18 of 51 pa-
tients. Of 51 patients, 15 were Philadelphia chromo-
some positive (Ph1). The CR rate was 77% among 
patients with baseline morphologic disease and 90%
among patients with baseline minimal disease. Patients 
attaining CR were found to be MRD-negative in 33 of 
39 cases where MRD-assessment was available. Fifteen 
of 33 patients attaining an MRD-negative CR relapsed, 
whereas 9 of 33 remained disease free with .1 year 
follow up. Severe CRS was seen in 44% of patients in 
the morphologic disease cohort and none of the patients 
in the minimal disease cohort. Grade 3/4 neurotoxicity 
occurred in 40% of patients with morphologic disease 
versus 14% of patients with minimal disease. A multi-
center phase II trial of this CAR-T product was opened 
in 2015; however, this trial was recently terminated 
after5 patients died due to treatment-related cerebral
edema.69,70,107 These results have not yet been
formally reported and the cause of the increased
toxicity on this trial remains unclear.
Investigators from UPenn also presented an update of
their trial of a 4-1BB–containing second-generation
CD19-specific CAR-T product at the 2016 ASCO
annual meeting.68 Thirty patients with relapsed or re-
fractory B-ALL, with a median age of approximately
44, were treated in 4-dosing cohorts. At least 9 patients
had earlier received blinatumumab and at least 9 pa-
tients had undergone earlier allogeneic HSCT. Grade
$3 CRS was reported in 22/30 patients, including 3
deaths due to severe CRS (each had received the highest
dose of CAR-Ts in a single infusion). Of note, grade$3
neurotoxicity was only reported in 1 of 30 patients.
The group at the FHCRC published the results of a
phase I/II trial of second-generation 4-1BB–containing
CD19-specific CAR-Ts in 30 adults (median age 40)
with relapsed or refractory B-ALL.55 Patients had
received a median of 3 previous lines of chemotherapy
and 11 of 30 patients had relapsed following allogeneic
HSCT. Before CAR-T infusion, patients were treated
with a cyclophosphamide-based lymphodepletion
regimen with or without the addition of fludarabine.
As discussed above, the investigators in this trial
selected for CD41 and CD81 cells, transduced each
subset separately, and then treated patients with a
defined 1:1 ratio of CD41:CD81CAR-Ts. Complete re-
missions were seen in 28 of 30 patients, and 26 of these
patients were negative for MRD. The addition of fludar-
abine was associated with an improvement in both
CAR-T persistence and disease-free survival with 12
of 17 such patients reported to be alive and in CR (me-
dian follow-up 300 days) compared with 1 of 13 patients
who received lymphodepletion with cyclophosphamide
alone (follow-up. 600 days). Severe CRSwas reported
in 7 of 30 patients and grade$3 neurotoxicity occurred
in 15 of 30 patients. One patient died due to severe CRS
and another due to irreversible neurotoxicity.
For pediatric ALL, the most extensive experience of
CD19-specific CAR-T therapy has come out of CHOP,
Seattle Children’s, and the NCI. At the 2016 ASCO
annual meeting, investigators from CHOP presented an
update on their largest trial to date of CD19-specific
CAR-Ts for pediatricALL, reporting outcomes for 60pa-
tients aged 1.7 to 24 (median 11) years. Of 60 patients, 39
had already undergone allogeneic HSCT, 44 had detect-
able disease at baseline, and 16 were in an MRD-
negative remission. Severe CRS was reported in
approximately 27% of patients. Of 60 patients, 56 at-
tained a CR and 51 of those patients were found to be
MRD negative. The 2-year relapse-free survival and
overall survival were 53% and 61%, respectively.
At the 2016 American Society of Hematology 
annual meeting, investigators from the NCI presented 
the outcomes of 51 pediatric patients with ALL who 
were treated with a second-generation CD19-specific 
CAR-T product containing the CD28 endodomain.59 
Eleven patients had primary refractory ALL, 5 had 
Ph1 disease, and 6 had CNS disease. Grade 3–4 
CRS was seen in 7 of 51 patients and grade 3 neuro-
toxicity was seen in 3 of 51 patients. Of 51 patients, 
31 attained a CR and 28 were found to be negative 
for MRD. The use of fludarabine/cyclophosphamide-
based lymphodepletion in 36 of 51 patients was asso-
ciated with significantly better outcomes, with a me-
dian overall survival of 13.3 months compared with 
5.5 months among patients receiving other lymphode-
pletion regimens.
Also at the 2016 American Society of Hematology 
annual meeting, investigators from Seattle Children’s re-
ported outcomes for 43 pediatric patients with B-ALL 
who were treated with CD19-specific CAR-Ts.53 
Similar to the adult-ALL trial at FHCRC discussed 
above, patients were infused with a defined composition 
of CD41:CD81 CAR-Ts. Severe CRS and severe neuro-
toxicity were both reported in 10 of 43 patients, with no 
reported deaths due to treatment-related toxicity. Of 43 
patients, 40 attained a CR and all were MRD negative. 
The 12-month overall survival was 70%.
Despite the impressive efficacy seen in trials of 
CD19-specific CAR-Ts to date, the significant rate of 
CRS and/or neurotoxicity, coupled with our lack of 
ability to accurately predict and effectively manage 
such toxicities, underscores the need for further opti-
mization before the wider application of CAR-T ther-
apies. Incorporating safety mechanisms into the CAR 
will likely prove to be an immediate and important 
component of this optimization. Alternatively, if 
proven to be scalable and highly reproducible, method-
ologies allowing the production of more uniform 
CAR-T products55 and gene-editing techniques that 
lead to more consistent CAR transgene expression44,46 
may represent valuable future approaches to better 
standardize therapeutic potential, while minimizing 
collateral toxicities.
Beyond CD19-specific CAR T-cells for B-cell 
malignancies. Although CD19 is highly expressed in 
B-cell leukemias and NHLs, many patients do not 
respond to CD19-directed therapy, and in certain 
patients who do initially respond, CD19-negative 
relapse has also been described.130 Additional targets 
are under investigation for the treatment of B-cell 
malignancies, including CD20, CD22, tyrosine 
kinase–like orphan receptor 1 (ROR1), and the k-light 
chain of human immunoglobulins.Shah et al.109 recently reported preliminary results of
a trial conducted at the NCI in which autologous CD22-
specific CAR-Ts were infused following lymphodeple-
tion with fludarabine and cyclophosphamide in 9
pediatric subjects with B-ALL. Of these patients, 7
had relapsed following previous CD19-specific
CAR-Ts and 6 were shown to have CD19dim/neg tumor
cells. Treatment-related toxicities included grade 3 diar-
rhea in 1 patient and grade #2 CRS in 7 patients. Of 9
patients, 7 obtained an MRD-negative CR and 3 were in
a sustained CR at 3 months.
A clinical trial was previously conducted at BCM
evaluating CAR-Ts targeting the k-light chain of human
immunoglobulins for the treatment of relapsed or refrac-
tory k-expressing NHL, CLL, or multiple myeloma
(MM).74 A total of 16 patients were treated, including
7 with NHL, 2 with CLL, and 7 with MM. Patients
received either no lymphodepletion or limited lympho-
depletion consisting of cyclophosphamide 12.5 mg/kg.
There were no grade $3 toxicities attributable to the
CAR-Ts; however, in patients withMM (who had higher
baseline B-cell counts), therewas evidence of a decrease
in normal circulating k-expressing B-cells. Of the pa-
tients with NHL/CLL, the ORRwas 3 of 9 and 2 patients
with DLBCL attained aCR (1 relapsed after 6weeks and
the other remained in CR at a follow-up of 32 months).
Third-generation CD20-specific CAR-Ts including
both the CD28 and 4-1BB costimulatory domains
have previously been evaluated by Till et al. at the
FHCRC. Three patients with B-cell NHL were treated.
One patient developed grade 3 hypoxemia potentially
related to CAR-Ts. Two patients without evaluable dis-
ease at baseline remained progression free for 12 and
24 months and a third patient attained a PR before re-
lapsing 12 months following CAR-T administration.
More recently, a second-generation CD20-specific
CAR-T product containing the CD28 costimulatory
domain was evaluated in a clinical trial at the Chinese
PLA General Hospital. Eleven patients with relapsed
or refractory B-NHLwere treated. No CRS or neurotox-
icity were observed. The ORRwas 9 of 11 (82%), with 6
patients achieving CR and a median progression-free
survival of 6 months (see Table II).112,113
ROR1 is another proposed target for the treatment of
B-cell malignancies. ROR1 is principally expressed
during embryonic development after which its expres-
sion is thought to be negligible in normal tissues.
ROR1 is aberrantly expressed by many malignancies,
however,131 and preclinical studies of ROR1-specific
CAR-Ts have shown promise.92 Clinical trials are
currently open at the FHCRC (for ROR1-positive
CLL, ALL, and mantle cell lymphoma)132 and at the
M.D. Anderson Cancer Center (MDACC; for CLL).133
NOVEL APPROACHES TO CAR T-CELL DESIGN
In addition to the evaluation of novel targets for 
CAR-Ts, many innovative approaches are being 
developed to both improve antitumor activity and to 
reduce toxicities. Examples include the development of 
CARs engineered to secrete proinflammatory cytokines 
to protect them from inhibitory signals in the tumor 
microenvironment, the inclusion of a cytokine-receptor 
in addition to the CAR to provide cytokine-mediated 
growth stimulation to the engineered T-cells, and the 
inclusion of natural killer cell receptors in engineered T-
cells to allow better discrimination between tumor cells 
and nonmalignant cells.134,135 Although a 
comprehensive discussion is beyond the scope of this 
review, several promising strategies are highlighted 
below.
Improving CAR T-cell specificity via dual antigen 
recognition. Given the challenges in identifying antigens 
that are truly specific to a given tumor, there has been 
significant interest in developing CAR-Ts that would 
require the recognition of multiple antigens in 
combination to exploit their full potential, thereby 
allowing better discrimination between tumor cells and 
normal tissue.136-139 One such approach has been the 
expression of two CARs on the same cell, each with a 
distinct scFv, and both with incomplete signaling 
domains such that simultaneous engagement of the two 
CARs would be required for optimal T-cell 
activation.139 Another approach has been the 
development of inhibitory CARs (iCARs) which 
incorporate the signaling domains of immunoinhibitory 
receptors (cytotoxic T-lymphocyte–associated protein 4 
or programmed cell death protein 1) with the goal of 
dampening T-cell activation in the presence of an 
antigen expressed on normal tissues, while allowing 
full T-cell activation via a separate CAR when the same 
cell encounters a different, tumor-associated antigen.137 
Roybal et al.138 recently described an innovative 
combinatorially activated T-cell circuit, which they 
termed a ‘‘Two Antigen AND-Gate Circuit,’’ whereby 
activation of a synthetic Notch receptor for one antigen 
induces the expression of a CAR targeted toward a 
second antigen. Although none of these techniques 
have yet been evaluated in humans, further 
development of clinically-feasible techniques to 
improve CAR-T specificity will likely be an important 
prerequisite to expanding the applicability of such 
therapies.
Strategies to prevent antigen escape. Whereas concern 
for off-target toxicities is driving efforts to improve 
CAR-T specificity, this has been somewhat less of a 
concern thus far in the development of CAR-Ts for B-
cell malignancies. Perhaps more relevant to B-cell 
malignancies, is the occurrence of disease relapses dueto antigen escape. Despite the successes of CD19-
directed CAR-Ts for B-ALL, CD19-negative relapse
has been reported in several trials.55,59,91,94 Several
mechanisms have been observed, including the
development of mutations in CD19, expression of
alternative splice variants of CD19, and complete loss
of CD19-expression, which was reported in a trial
among 2 patients who developed a relapse due to
myeloid lineage switch, both harboring a
rearrangement of the mixed lineage leukemia
gene.130,140 One strategy for B-ALL has been to
target alternative surface antigens other than CD19, and
as mentioned above, a trial recently investigated the use
of CD22-directed CAR-Ts for relapsed pediatric
B-ALL.109 Although not yet evaluated in clinical trials,
there has also been substantial interest in the possibility
of targeting two or more antigens simultaneously,
which could potentially be accomplished by pooling
CAR-T products, expressing multiple CARs in the
same cells, or designing CARs that include two scFvs
in tandem.140
Universal CARs. Technical or economic challenges
associated with the production of autologous cellular
products may also limit the widespread clinical applica-
bility of CAR-Ts. Inadequate leukapheresis, failure of
CAR-T manufacturing, and rapid progression of the
disease while CAR-Ts are being generated may all
cause severe limitations for the routine use of CAR-
Ts. Banked, third-party CAR-Ts have been evaluated
in the context of concurrent or prior HSCT, with
CAR-Ts derived from the patient’s donor
lymphocytes; however, many of the same challenges
remain with donor-derived CAR-Ts, and such
therapies are only potentially applicable to a minority
of patients. The heterogeneity of both autologous and
donor-derived allogeneic CAR-Ts also presents
several challenges, including unpredictable efficacy
and toxicity. In an attempt to develop ‘‘universal’’
CAR-Ts that could be produced in a standardized
fashion from T-cells derived from one or more healthy
unmatched donors, with subsequent administration to
multiple patients, several groups have developed gene-
editing techniques such as prokaryotic type II
CRISPR-Cas9, transcription activator-like effector
nucleases, and zinc-finger nucleases to eliminate
endogenous ab-TCR expression in T-cells to remove
the risk of inducing graft-versus-host disease.141-144
Investigators at the University College of London
demonstrated the possibility of using transcription
activator-like effector nuclease gene-editing
techniques to produce T-cells deficient in expression
of both the endogenous ab-TCR and CD52 (for the
purposes of inducing recipient immunosuppression by
using the anti-CD52 monoclonal antibody, 
alemtuzumab), with subsequent lentiviral transduction 
to express a CD19-specific CAR.141 Initial clinical 
assessment of this ‘‘off the shelf’’ CAR-T product in 2 
infants with relapsed/refractory CD191 B-ALL 
produced ongoing molecular remission in both 
patients (see Table I)37,38 and larger clinical trials are 
underway to further validate this approach.145,146
CONCLUSIONS
The field of cancer immunotherapy has seen remark-
able advances over the past decade, leading to long-term 
remissions in diseases that would otherwise be rapidly 
fatal. The theoretical benefit of redirecting the immune 
system to target cancer cells has long been appreciated, 
but it was not until the development of immune check-
point inhibitors that this potential became a reality for 
large numbers of patients. As is clear from the clinical 
trials discussed above, CAR-Ts have given us the ability 
to further unleash the power of cell-mediated immunity 
against cancer cells, now in a highly-targeted manner 
that has not previously been possible. This has led to un-
precedented successes in the treatment of B-ALL and 
other B-cell malignancies, and we remain hopeful that 
similar successes will soon be replicated in other hema-
tologic malignancies and in solid tumors. Combination 
with other immunotherapeutics is also likely to further 
maximize the potential of CAR-Ts.147 While the power 
of CAR-Ts is clear, it is also clear that we require a bet-
ter understanding of how these artificially created recep-
tors interact with the complex signaling networks of the 
immune system. Further elucidation of the biology of 
CAR-Ts and their downstream effects will allow us to 
minimize unpredictable toxicities and improve their 
therapeutic potential.ACKNOWLEDGMENTS
Conflicts of Interest: All authors have read the 
journal’s policy on disclosure of potential conflicts of 
interest and have none to declare. The manuscript has 
been reviewed and approved by all named authors. 
This work was supported in part by a grant from the 
University Cancer Research Fund (UCRF, grant no: 
2015-T2-08).1. Sun C, Dotti G, Savoldo B. Utilizing cell-based therapeutics to
overcome immune evasion in hematologic malignancies. Blood
2016;127:3350–9.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: inte-
grating immunity’s roles in cancer suppression and promotion.
Science 2011;331:1565–70.
3. Gaillard H, Garcia-Muse T, Aguilera A. Replication stress and
cancer. Nat Rev Cancer 2015;15:276–89.
REFERENCES4. Billingham RE, Brent L, Medawar PB. Quantitative studies on
tissue transplantation immunity. II. The origin, strength and
duration of actively and adoptively acquired immunity. Proc R
Soc Lond B Biol Sci 1954;143:58–80.
5. Gross G,Waks T, Eshhar Z. Expression of immunoglobulin-T-cell
receptor chimericmolecules as functional receptorswithantibody-
type specificity. Proc Natl Acad Sci U S A 1989;86:10024–8.
6. Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of
chimeric receptor composed of immunoglobulin-derived V re-
gions and T-cell receptor-derived C regions. Biochem Biophys
Res Commun 1987;149:960–8.
7. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell
therapy: 25years in the making. Blood Rev 2016;30:157–67.
8. Chen L, Ashe S, BradyWA, et al. Costimulation of antitumor im-
munity by the B7 counterreceptor for the T lymphocyte mole-
cules CD28 and CTLA-4. Cell 1992;71:1093–102.
9. Chen L, Flies DB. Molecular mechanisms of T cell co-
stimulation and co-inhibition. Nat Rev Immunol 2013;13:
227–42.
10. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Hu-
man T-cell clonal anergy is induced by antigen presentation in
the absence of B7 costimulation. Proc Natl Acad Sci U S A
1993;90:6586–90.
11. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation
and targeting of cytotoxic lymphocytes through chimeric single
chains consisting of antibody-binding domains and the gamma
or zeta subunits of the immunoglobulin and T-cell receptors.
Proc Natl Acad Sci U S A 1993;90:720–4.
12. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized
study of HIV-specific T-cell gene therapy in subjects with unde-
tectable plasma viremia on combination antiretroviral therapy.
Mol Ther 2002;5:788–97.
13. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells en-
gineered to coexpress tumor-specific receptors: persistence and
antitumor activity in individuals with neuroblastoma. Nat Med
2008;14:1264–70.
14. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-
term fate of chimeric antigen receptor-positive T cells in patients
with neuroblastoma. Blood 2011;118:6050–6.
15. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of
metastatic renal cell carcinoma with CAIX CAR-engineered T
cells: clinical evaluation and management of on-target toxicity.
Mol Ther 2013;21:904–12.
16. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of
chimeric antigen receptor re-directed cytolytic T lymphocyte
clones in patientswith neuroblastoma.Mol Ther 2007;15:825–33.
17. KershawMH,Westwood JA, Parker LL, et al. A phase I study on
adoptive immunotherapy using gene-modified T cells for
ovarian cancer. Clin Cancer Res 2006;12:6106–15.
18. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for
indolent non-Hodgkin lymphoma and mantle cell lymphoma us-
ing genetically modified autologous CD20-specific T cells.
Blood 2008;112:2261–71.
19. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejec-
tion responses contribute to attenuated persistence of adoptively
transferred CD20/CD19-specific chimeric antigen receptor re-
directed T cells in humans. Biol Blood Marrow Transplant
2010;16:1245–56.
20. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and
development of therapies using chimeric antigen receptor-
expressing T cells. Immunol Rev 2014;257:107–26.
21. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional
oncogenesis in 4 patients after retrovirus-mediated gene therapy
of SCID-X1. J Clin Invest 2008;118:3132–42.
22. von Kalle C, Deichmann A, Schmidt M. Vector integration and
tumorigenesis. Hum Gene Ther 2014;25:475–81.
23. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety
and function of retroviral-modified chimeric antigen receptor T
cells. Sci Transl Med 2012;4:132ra153.
24. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric
receptors providing both primary and costimulatory signaling
in T cells from a single gene product. J Immunol 1998;161:
2791–7.
25. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation im-
proves expansion and persistence of chimeric antigen receptor-
modified T cells in lymphoma patients. J Clin Invest 2011;121:
1822–6.
26. Imai C, Mihara K, AndreanskyM, et al. Chimeric receptors with
4-1BB signaling capacity provoke potent cytotoxicity against
acute lymphoblastic leukemia. Leukemia 2004;18:676–84.
27. Carpenito C, Milone MC, Hassan R, et al. Control of large, es-
tablished tumor xenografts with genetically retargeted human
T cells containing CD28 and CD137 domains. Proc Natl Acad
Sci U S A 2009;106:3360–5.
28. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M.
Chimeric antigen receptors combining 4-1BB and CD28
signaling domains augment PI3kinase/AKT/Bcl-XL activation
and CD81 T cell-mediated tumor eradication. Mol Ther 2010;
18:413–20.
29. Gomes da Silva D, Mukherjee M, Srinivasan M, et al. Direct
comparison of in vivo fate of second and third-generation
CD19-specific chimeric antigen receptor (CAR)-T cells in pa-
tients with B-Cell lymphoma: Reversal of toxicity from tonic
signaling. Blood 2016;128:1851.
30. Geldres C, Savoldo B, Dotti G. Chimeric antigen receptor-
redirected T cells return to the bench. Semin Immunol 2016;
28:3–9.
31. Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, et al. Geneti-
cally engineered T cells bearing chimeric nanoconstructed re-
ceptors harboring TAG-72-specific camelid single domain
antibodies as targeting agents. Cancer Lett 2013;334:237–44.
32. Zhang AH, Yoon JH, Kim YC, Scott DW. Targeting FVIII-
specific B cells using BAR-transduced regulatory T cells. Blood
2016;128:329.
33. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-
derived CD19-redirected virus-specific T cells for B-cell malig-
nancies relapsed after allogeneic stem cell transplant: a phase 1
study. Blood 2013;122:2965–73.
34. Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that
express an anti-CD19 chimeric antigen receptor induce remis-
sions of B-Cell malignancies that progress after allogeneic
hematopoietic stem-cell transplantation without causing graft-
versus-host disease. J Clin Oncol 2016;34:1112–21.
35. Kebriaei P, Singh H, Huls MH, et al. Phase I trials using Sleeping
Beauty to generate CD19-specific CAR T cells. J Clin Invest
2016;126:3363–76.
36. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-
lineage cells and regression of lymphoma in a patient treated
with autologous T cells genetically engineered to recognize
CD19. Blood 2010;116:4099–102.
37. QasimW, ZhanH, Samarasinghe S, et al. Molecular remission of
infant B-ALL after infusion of universal TALEN gene-edited
CAR T cells. Sci Transl Med 2017;9.
38. QasimW, Amrolia PJ, Samarasinghe S, et al. First clinical appli-
cation of Talen engineered universal CAR19 T cells in B-ALL.
Blood 2015;126:2046.
39. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell
gene transfer in a tumor-prone mouse model uncovers lowgenotoxicity of lentiviral vector integration. Nat Biotechnol
2006;24:687–96.
40. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells
to augment disease control in patients undergoing autologous he-
matopoietic stem-cell transplantation for advanced B-lymphoid
malignancies. Hum Gene Ther 2012;23:444–50.
41. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/
transposase system to generate CD19-specific T cells for the
treatment of B-lineage malignancies. Hum Gene Ther 2010;
21:427–37.
42. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive
immunotherapy for lymphoma using a chimeric antigen receptor
with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood 2012;119:3940–50.
43. Ellis J. Silencing and variegation of gammaretrovirus and lenti-
virus vectors. Hum Gene Ther 2005;16:1241–6.
44. Eyquem J,Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to
the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Nature 2017;543:113–7.
45. Schumann K, Lin S, Boyer E, et al. Generation of knock-in pri-
mary human T cells using Cas9 ribonucleoproteins. Proc Natl
Acad Sci U S A 2015;112:10437–42.
46. MacLeod DT, Antony J, Martin AJ, et al. Integration of a CD19
CAR into the TCR Alpha Chain Locus Streamlines Production
of Allogeneic Gene-Edited CAR T Cells. Mol Ther 2017;25:
949–61.
47. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset
with stem cell-like properties. Nat Med 2011;17:1290–7.
48. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C,
Riddell SR. Adoptive transfer of effector CD81 T cells derived
from central memory cells establishes persistent T cell memory
in primates. J Clin Invest 2008;118:294–305.
49. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively trans-
ferred effector cells derived from naive rather than central mem-
ory CD81 T cells mediate superior antitumor immunity. Proc
Natl Acad Sci U S A 2009;106:17469–74.
50. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full
effector function in vitro paradoxically impairs the in vivo anti-
tumor efficacy of adoptively transferred CD81 T cells. J Clin
Invest 2005;115:1616–26.
51. Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory
stem cells correlate with in vivo expansion of CAR.CD19-T cells
and are preserved by IL-7 and IL-15. Blood 2014;123:3750–9.
52. Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct
the generation of humanmemory stem T cells from naive precur-
sors. Blood 2013;121:573–84.
53. Gardner R, Finney O, Smithers H, et al. CD19CAR T cell prod-
ucts of defined CD4:CD8 composition and transgene expression
show prolonged persistence and durable MRD-negative remis-
sion in pediatric and young adult B-Cell all. Blood 2016;128:
219.
54. Turtle CJ, Hanafi LA, Berger C, et al. Rate of durable complete
response in ALL, NHL, and CLL after immunotherapy with
optimized lymphodepletion and defined composition CD19
CAR-T cells. J Clin Oncol 2016;34 (suppl; abstr 102).
55. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of
defined CD41:CD81 composition in adult B cell ALL patients.
J Clin Invest 2016;126:2123–38.
56. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for
patients with metastatic melanoma: evaluation of intensive mye-
loablative chemoradiation preparative regimens. J Clin Oncol
2008;26:5233–9.
57. Dai H, Zhang W, Li X, et al. Tolerance and efficacy of autolo-
gous or donor-derived T cells expressing CD19 chimeric antigen
receptors in adult B-ALL with extramedullary leukemia. On-
coimmunology 2015;4:e1027469.
58. Turtle CJ, Hanafi LA, Berger C, et al. Addition of fludarabine to
cyclophosphamide lymphodepletion improves in vivo expansion
of CD19 chimeric antigen receptor-modified T cells and clinical
outcome in adults with B cell acute lymphoblastic leukemia.
Blood 2015;126:3773.
59. Lee DW, Stetler-Stevenson M, Yuan CM, et al. Long-term out-
comes following CD19 CART cell therapy for B-ALL are supe-
rior in patients receiving a fludarabine/cyclophosphamide
preparative regimen and post-CAR hematopoietic stem cell
transplantation. Blood 2016;128:218.
60. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen re-
ceptor T cells: recognition and management. Blood 2016;127:
3321–30.
61. Lee DW, Gardner R, Porter DL, et al. Current concepts in the
diagnosis and management of cytokine release syndrome. Blood
2014;124:188–95.
62. Porter DL, HwangWT, FreyNV, et al. Chimeric antigen receptor
T cells persist and induce sustained remissions in relapsed re-
fractory chronic lymphocytic leukemia. Sci Transl Med 2015;
7:303ra139.
63. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity man-
agement of 19-28z CAR T cell therapy in B cell acute lympho-
blastic leukemia. Sci Transl Med 2014;6:224ra225.
64. Common Terminology Criteria for Adverse Events (CTCAE)
Version 4.03. US Department of Health and Human Services,
Bethesda, MD, 2010.
65. Bedoya F, Frigault MJ, Maus MV. The flipside of the power of
engineered T cells: observed and potential toxicities of geneti-
cally modified T cells as therapy. Mol Ther 2017;25:314–20.
66. Kenderian SS, Ruella M, Shestova O, et al. Ruxolitinib prevents
cytokine release syndrome after CART cell therapy without im-
pairing the anti-tumor effect in a xenograft model. Blood 2016;
128:652.
67. RuellaM, Kenderian SS, Shestova O, et al. Kinase inhibitor ibru-
tinib prevents cytokine-release syndrome after anti-CD19
chimeric antigen receptor T cells (CART) for B cell neoplasms.
Blood 2016;128:2159.
68. FreyN, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen
receptor (CAR) T cell therapy for adult patients with relapsed or
refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin On-
col 2016;34 (suppl; abstr 7002).
69. Juno Therapeutics, Inc. Study Evaluating the Efficacy and Safety
of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-
ALL) (ROCKET). In: ClinicalTrials.gov [Internet]. Bethesda
(MD): National Library of Medicine (US). Available at:
https://clinicaltrials.gov/ct2/show/NCT02535364; 2000. Accessed
March 17, 2017. NLM Identifier: NCT02535364.
70. Juno Therapeutics Inc. Juno Therapeutics Reports Fourth
Quarter and 2016 Financial Results. Available at: http://ir.
junotherapeutics.com/phoenix.zhtml?c5253828&p5irol-news
Article&ID52250772; 2017. Accessed March 6, 2017.
71. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syn-
drome after chimeric antigen receptor T cell therapy for acute
lymphoblastic leukemia. Crit Care Med 2017;45:e124–31.
72. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predic-
tive biomarkers for cytokine release syndrome after chimeric an-
tigen receptor T-cell therapy for acute lymphoblastic leukemia.
Cancer Discov 2016;6:664–79.
73. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM,
Rosenberg SA. Case report of a serious adverse event following
the administration of T cells transduced with a chimeric antigen
receptor recognizing ERBB2. Mol Ther 2010;18:843–51.74. Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with
T lymphocytes targeting malignancy-associated kappa light
chains. J Clin Invest 2016;126:2588–96.
75. Holzinger A, BardenM, Abken H. The growing world of CART
cell trials: a systematic review. Cancer Immunol Immunother
2016;65:1433–50.
76. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer
into donor lymphocytes for control of allogeneic graft-versus-
leukemia. Science 1997;276:1719–24.
77. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-
gene-engineered donor lymphocytes after family haploidentical
haemopoietic stem-cell transplantation for leukaemia (the
TK007 trial): a non-randomised phase I-II study. Lancet Oncol
2009;10:489–500.
78. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of
transgene-specific immune responses that limit the in vivo
persistence of adoptively transferred HSV-TK-modified donor
T cells after allogeneic hematopoietic cell transplantation. Blood
2006;107:2294–302.
79. Diaconu I, Ballard B, ZhangM, et al. Inducible Caspase-9 selec-
tively modulates the toxicities of CD19-specific chimeric anti-
gen receptor-modified T cells. Mol Ther 2017;25:580–92.
80. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety
switch for adoptive cell therapy. N Engl J Med 2011;365:
1673–83.
81. Baylor College ofMedicine. 3rd Generation GD-2 Chimeric An-
tigen Receptor and iCaspase Suicide Safety Switch, Neuroblas-
toma, GRAIN (GRAIN). In: ClinicalTrials.gov [Internet].
Bethesda (MD): National Library of Medicine (US). Available
at: https://clinicaltrials.gov/ct2/show/NCT01822652; 2000. Ac-
cessed March 7, 2017. NLM Identifier: NCT01822652.
82. National Cancer Institute (NCI). A Phase I Trial of T Cells Ex-
pressing an Anti-GD2 Chimeric Antigen Receptor in Children
and YoungAdultsWith GD21 Solid Tumors. In: ClinicalTrials.-
gov [Internet]. Bethesda (MD): National Library of Medicine
(US). Available at: https://clinicaltrials.gov/ct2/show/
NCT02107963; 2000. Accessed March 17, 2017. NLM Identi-
fier: NCT02107963.
83. Memorial Sloan Kettering Cancer Center. Malignant Pleural
Disease Treated With Autologous T Cells Genetically Engi-
neered to Target the Cancer-Cell Surface Antigen Mesothelin.
In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Li-
brary of Medicine (US). Available at: https://clinicaltrials.gov/
ct2/show/NCT02414269; 2000. Accessed March 17, 2017.
NLM Identifier: NCT02414269.
84. Peking University. Evaluation of 4th Generation Safety-
designed CAR T Cells Targeting High-risk and Refractory B
Cell Lymphomas (4SCAR19273). In: ClinicalTrials.gov
[Internet]. Bethesda (MD): National Library of Medicine (US).
Available at: https://clinicaltrials.gov/ct2/show/NCT
02247609; 2000. Accessed March 7, 2017. NLM Identifier:
NCT02247609.
85. Shenzhen Geno-Immune Medical Institute. A Phase I/II Multi-
ple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed
and Refractory B Cell Malignancies. In: ClinicalTrials.gov
[Internet]. Bethesda (MD): National Library of Medicine (US).
Available at: https://clinicaltrials.gov/ct2/show/NCT0
3050190; 2000. Accessed March 7, 2017. NLM Identifier:
NCT03050190.
86. UNC Lineberger Comprehensive Cancer Center. Administration
of Autologous CAR-T CD19 Antigen With Inducible Safety
Switch in Patients With Relapsed/Refractory Acute Lympho-
blastic Leukemia. In: ClinicalTrials.gov [Internet]. Bethesda
(MD): National Library of Medicine (US). Available at:
https://clinicaltrials.gov/ct2/show/NCT03016377; 2000. Ac-
cessed March 7, 2017. NLM Identifier: NCT03016377.
87. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell
surface polypeptide for selection, in vivo tracking, and ablation
of engineered cells. Blood 2011;118:1255–63.
88. Brentjens R, Riviere I, Hollyman D, et al. 401. Unexpected
toxicity of cyclophosphamide followed by adoptively transferred
CD19-targeted T cells in a patient with Bulky CLL. Mol Ther
2009;17:S157.
89. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric an-
tigen receptor-modified T cells in chronic lymphoid leukemia. N
Engl J Med 2011;365:725–33.
90. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric an-
tigen receptors have potent antitumor effects and can establish
memory in patients with advanced leukemia. Sci Transl Med
2011;3:95ra73.
91. Lee DW,Kochenderfer JN, Stetler-StevensonM, et al. T cells ex-
pressing CD19 chimeric antigen receptors for acute lympho-
blastic leukaemia in children and young adults: a phase 1
dose-escalation trial. Lancet 2015;385:517–28.
92. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T
cells for sustained remissions in leukemia. N Engl J Med 2014;
371:1507–17.
93. Kochenderfer JN, DudleyME, Kassim SH, et al. Chemotherapy-
refractory diffuse large B-cell lymphoma and indolent B-cell
malignancies can be effectively treated with autologous T cells
expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol
2015;33:540–9.
94. Maude SL, Teachey DT, Rheingold SR, et al. Sustained remis-
sions with CD19-specific chimeric antigen receptor (CAR)-
modified T cells in children with relapsed/refractory ALL. J
Clin Oncol 2016;34 (suppl; abstr 3011).
95. Grupp SA, Maude SL, Shaw PA, et al. Durable remissions in
children with relapsed/refractory ALL treated with T Cells engi-
neered with a CD19-targeted chimeric antigen receptor
(CTL019). Blood 2015;126:681.
96. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-
modified T cells for acute lymphoid leukemia. N Engl J Med
2013;368:1509–18.
97. Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global
registration trial of the efficacy and safety of CTL019 in pediatric
and young adults with relapsed/refractory acute lymphoblastic
leukemia (all). Blood 2016;128:221.
98. Maude SL, Pulsipher MA, Boyer MW, et al. Efficacy and safety
of CTL019 in the first us phase II multicenter trial in pediatric
relapsed/refractory acute lymphoblastic leukemia: results of an
interim analysis. Blood 2016;128:2801.
99. Maude SL, Barrett DM, Rheingold SR, et al. Efficacy of human-
ized CD19-targeted chimeric antigen receptor (CAR)-modified
T cells in children with relapsed ALL. J Clin Oncol 2016;34
(suppl; abstr 3007).
100. Maude SL, Barrett DM, Rheingold SR, et al. Efficacy of human-
ized CD19-targeted chimeric antigen receptor (CAR)-modified
T cells in children and young adults with relapsed/refractory
acute lymphoblastic leukemia. Blood 2016;128:217.
101. Chang LJ, Dong L, Liu YC, et al. Safety and efficacy eval-
uation of 4SCAR19 chimeric antigen receptor-modified T
cells targeting B cell acute lymphoblastic leukemia–three-
year follow-up of a multicenter phase I/II study. Blood
2016;128:587.
102. Deng B, Chang AH, Yang J, et al. Safety and efficacy of low dose
CD19 targeted chimeric antigen receptor T (CAR-T) cell immu-
notherapy in 47 cases with relapsed refractory B-cell acute
lymphoblastic leukemia (B-ALL). Blood 2016;128:649.103. Park JH, Riviere I, Wang X, Purdon T, SadelainM, Brentjens RJ.
Impact of disease burden on long-term outcome of 19-28z CAR
modified T cells in adult patients with relapsed B-ALL. J Clin
Oncol 2016;34 (suppl; abstr 7003).
104. Park JH, Riviere I, Wang X, et al. Implications of minimal resid-
ual disease negative complete remission (MRD-CR) and alloge-
neic stem cell transplant on safety and clinical outcome of
CD19-targeted 19-28z CAR modified T cells in adult patients
with relapsed, refractory B-Cell ALL. Blood 2015;126:682.
105. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells
rapidly induce molecular remissions in adults with
chemotherapy-refractory acute lymphoblastic leukemia. Sci
Transl Med 2013;5:177ra138.
106. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of
adoptively transferred autologous CD19-targeted T cells in pa-
tients with relapsed or chemotherapy refractory B-cell leuke-
mias. Blood 2011;118:4817–28.
107. Dyer O. FDA lifts hold on cancer immunotherapy trial placed af-
ter patients died. BMJ 2016;354.
108. Shah B, Huynh V, Sender LS, et al. High rates of minimal resid-
ual disease-negative (MRD2) complete responses (CR) in adult
and pediatric and patients with relapsed/refractory acute
lymphoblastic leukemia (R/R all) treated with KTE-C19 (Anti-
CD19 chimeric antigen receptor [CAR] T cells): preliminary re-
sults of the ZUMA-3 and ZUMA-4 trials. Blood 2016;128:2803.
109. Shah NN, Stetler-Stevenson M, Yuan CM, et al. Minimal resid-
ual disease negative complete remissions following anti-CD22
chimeric antigen receptor (CAR) in children and young adults
with relapsed/refractory acute lymphoblastic leukemia (ALL).
Blood 2016;128:650.
110. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell
depletion and remissions of malignancy along with cytokine-
associated toxicity in a clinical trial of anti-CD19 chimeric-anti-
gen-receptor-transduced T cells. Blood 2012;119:2709–20.
111. Sauter CS, Riviere I, Bernal Y, et al. Phase I trial of 19-28z
chimeric antigen receptor modified T cells (19-28z CAR-T)
post-high dose therapy and autologous stem cell transplant
(HDT-ASCT) for relapsed and refractory (rel/ref) aggressive
B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2015;
33 (suppl; abstr 8515).
112. Zhang W, Wang Y, Guo Y, et al. Treatment of CD20-directed
chimeric antigen receptor-modified T cells in patients with
relapsed or refractory B-cell non-Hodgkin lymphoma: an early
phase IIa trial report. Signal Transduct Target Ther 2016;1:1.
113. Wang Y, Zhang WY, Han QW, et al. Effective response and
delayed toxicities of refractory advanced diffuse large B-cell
lymphoma treated by CD20-directed chimeric antigen
receptor-modified T cells. Clin Immunol 2014;155:160–75.
114. Turtle CJ, Hanafi L-A, Li D, et al. CD19 CAR-T cells are highly
effective in ibrutinib-refractory chronic lymphocytic leukemia.
Blood 2016;128:56.
115. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-
Hodgkin’s lymphoma with a defined ratio of CD81 and
CD41 CD19-specific chimeric antigen receptor-modified T
cells. Sci Transl Med 2016;8:355ra116.
116. Turtle CJ, Berger C, Sommermeyer D, et al. Anti-CD19 chimeric
antigen receptor-modified T cell Therapy for B Cell non-
Hodgkin lymphoma and chronic lymphocytic leukemia: fludar-
abine and cyclophosphamide lymphodepletion improves
in vivo expansion and persistence of CAR-T cells and clinical
outcomes. Blood 2015;126:184.
117. Geyer MB, Park JH, Riviere I, et al. Implications of concurrent
ibrutinib therapy on CAR T-cell manufacturing and phenotype
and on clinical outcomes following CD19-targeted CAR T-cell
administration in adults with relapsed/refractory CLL. Blood
2016;128:58.
118. Neelapu SS, Locke FL, Bartlett NL, et al. A phase 2 multicenter
trial of KTE-C19 (anti-CD19 CART cells) in patients with che-
morefractory primary mediastinal B-Cell lymphoma (PMBCL)
and transformed follicular lymphoma (TFL): interim results
from ZUMA-1. Blood 2016;128:998.
119. Abramson JS, Palomba L, Gordon LI, et al. Transcend NHL 001:
immunotherapy with the CD19-directed CAR T-cell product
JCAR017 results in high complete response rates in relapsed or re-
fractory B-Cell non-Hodgkin lymphoma. Blood 2016;128:4192.
120. Kochenderfer JN, Somerville RP, Lu T, et al. Anti-CD19
chimeric antigen receptor T cells preceded by low-dose chemo-
therapy to induce remissions of advanced lymphoma. J Clin On-
col 2016;34 (suppl; abstr LBA3010).
121. Brudno JN, Shi V, Stroncek D, et al. T cells expressing a novel
fully-human anti-CD19 chimeric antigen receptor induce remis-
sions of advanced lymphoma in a first-in-humans clinical trial.
Blood 2016;128:999.
122. Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II
dose optimization study of chimeric antigen receptor modified T
cells directed against CD19 (CTL019) in patients with relapsed,
refractory CLL. Blood 2014;124:1982.
123. PorterDL, FreyN,Melenhorst JJ, et al.Randomized, phase II dose
optimization study of chimeric antigen receptor (CAR) modified
T cells directed against CD19 in patients (pts) with relapsed, re-
fractory (R/R) CLL. J Clin Oncol 2016;34 (suppl; abstr 3009).
124. Schuster SJ, Svoboda J, Nasta S, et al. Phase IIa trial of chimeric
antigen receptor modified T cells directed against CD19
(CTL019) in patients with relapsed or refractory CD191 lym-
phomas. J Clin Oncol 2015;33 (suppl; abstr 8516).
125. Schuster SJ, Svoboda J, Nasta SD, et al. Treatment with chimeric
antigen receptor modified T cells directed against CD19
(CTL019) results in durable remissions in patients with relapsed
or refractory diffuse large B cell lymphomas of germinal center
and non-germinal center origin, ‘‘Double Hit’’ diffuse large B
cell lymphomas, and transformed follicular to diffuse large B
cell lymphomas. Blood 2016;128:3026.
126. Chong EA, Svoboda J, Nasta SD, et al. Chimeric antigen recep-
tor modified T cells directed against CD19 (CTL019) in patients
with poor prognosis, relapsed or refractory CD191 follicular
lymphoma: prolonged remissions relative to antecedent therapy.
Blood 2016;128:1100.
127. Schuster SJ, Svoboda J, Dwivedy Nasta S, et al. Phase IIa trial of
chimeric antigen receptor modified T cells directed against
CD19 (CTL019) in patients with relapsed or refractory
CD191 lymphomas. Blood 2014;124:3087.
128. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of
ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T
cell therapy in refractory aggressive lymphoma. Mol Ther
2017;25:285–95.
129. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 clinical results
of the ZUMA-1 (KTE-C19-101) study: a phase 1-2 multi-center
study evaluating the safety and efficacy of anti-CD19 CAR T
cells (KTE-C19) in subjects with refractory aggressive non-
Hodgkin lymphoma (NHL). Blood 2015;126:3991.
130. Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-
negative myeloid phenotype allows immune escape of MLL-
rearranged B-ALL from CD19 CAR-T-cell therapy. Blood
2016;127:2406–10.
131. Deniger DC, Yu J, Huls MH, et al. Sleeping beauty transposition
of chimeric antigen receptors targeting receptor tyrosine kinase-
like orphan Receptor-1 (ROR1) into diverse memory T-cell pop-
ulations. PLoS One 2015;10:e0128151.132. Fred Hutchinson Cancer Research Center. Genetically Modified
T-Cell Therapy in Treating Patients With Advanced ROR11
Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda
(MD): National Library of Medicine (US). Available at:
https://clinicaltrials.gov/ct2/show/NCT02706392; 2000. Ac-
cessed March 7, 2017. NLM Identifier: NCT02706392.
133. M.D. Anderson Cancer Center. Autologous ROR1R-CAR-T
Cells for Chronic Lymphocytic Leukemia (CLL). In: Clinical-
Trials.gov [Internet]. Bethesda (MD): National Library of Med-
icine (US). Available at: https://clinicaltrials.gov/ct2/show/
NCT02194374; 2000. Accessed March 7, 2017. NLM Identifier:
NCT02194374.
134. Jackson HJ, Rafiq S, Brentjens RJ. Driving CART-cells forward.
Nat Rev Clin Oncol 2016;13:370–83.
135. Fesnak AD, June CH, Levine BL. Engineered T cells: the prom-
ise and challenges of cancer immunotherapy. Nat Rev Cancer
2016;16:566–81.
136. Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of
ErbB2 andMUC1 in breast cancer using chimeric antigen recep-
tors engineered to provide complementary signaling. J Clin Im-
munol 2012;32:1059–70.
137. Fedorov VD, Themeli M, SadelainM. PD-1- and CTLA-4-based
inhibitory chimeric antigen receptors (iCARs) divert off-target
immunotherapy responses. Sci Transl Med 2013;5:215ra172.
138. Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor Recogni-
tion by T Cells with combinatorial antigen-sensing circuits. Cell
2016;164:770–9.
139. Kloss CC, Condomines M, Cartellieri M, Bachmann M,
Sadelain M. Combinatorial antigen recognition with balanced
signaling promotes selective tumor eradication by engineered
T cells. Nat Biotechnol 2013;31:71–5.
140. Ruella M, Maus MV. Catch me if you can: leukemia escape after
CD19-directed T cell immunotherapies. Comput Struct Bio-
technol J 2016;14:357–62.
141. Poirot L, PhilipB, Schiffer-ManniouiC, et al.Multiplex genome-
edited T-cell manufacturing platform for ‘‘Off-the-Shelf’’ adop-
tive T-cell immunotherapies. Cancer Res 2015;75:3853–64.
142. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-
cell based immunotherapy: T cells engineered to express a
CD19-specific chimeric-antigen-receptor and eliminate expres-
sion of endogenous TCR. Blood 2012;119:5697–705.
143. Valton J, Guyot V, Marechal A, et al. A multidrug-resistant engi-
neered CAR T cell for allogeneic combination immunotherapy.
Mol Ther 2015;23:1507–18.
144. Osborn MJ, Webber BR, Knipping F, et al. Evaluation of TCR
gene editing achieved by TALENs, CRISPR/Cas9, and mega-
TAL nucleases. Mol Ther 2016;24:570–81.
145. Institut deRecherches Internationales Servier. StudyofUCART19
in Pediatric Patients With Relapsed/Refractory BAcute Lympho-
blastic Leukemia (PALL). In: ClinicalTrials.gov [Internet]. Be-
thesda (MD): National Library of Medicine (US); 2000.
Available at: https://clinicaltrials.gov/ct2/show/NCT02808442;
2000. AccessedMarch 17, 2017. NLM Identifier: NCT02808442.
146. Servier. Dose Escalation Study to Evaluate the Safety, Tolera-
bility and Biological Activity of a Single Dose of UCART19 in
Patients With Relapsed/Refractory (R/R) B-cell Acute Lympho-
blastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia
(CLL) (CALM). In: ClinicalTrials.gov [Internet]. Bethesda
(MD): National Library of Medicine (US); 2000. Available at:
https://clinicaltrials.gov/ct2/show/NCT02746952; 2000. Ac-
cessed March 17, 2017. NLM Identifier: NCT02746952.
147. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of
cancer treatment: immunomodulation, CARs and combination
immunotherapy. Nat Rev Clin Oncol 2016;13:273–90.
